Introduction {#s1}
============

Rett Syndrome (RTT) is a devastating, X-linked neurodevelopmental disorder marked by a developmental stagnation and regression in neurological function. Early on these neurological deficits often have autistic-like features and are accompanied by an array of somatic impairments ([@bib9]; [@bib71]; [@bib42]). Since the discovery that mutations in the transcriptional regulator Methyl-CpG-binding protein 2 (*Mecp2*) underlie the vast majority of RTT cases, studies in mouse models of RTT have implicated virtually every resident brain cell type (neurons and glia) in the disorder ([@bib1]; [@bib26]; [@bib48]; [@bib45]; [@bib40]). However, it remains unclear which cell types primarily contribute to each phenotype and how these vastly different cell types work in concert with each other to initiate and propagate the disorder.

Microglia, the brain resident myeloid-derived cell, are among the most recent cell types implicated in RTT pathogenesis ([@bib19]; [@bib15]; [@bib37]; [@bib47]). However, the data have been a subject of increasing controversy ([@bib67]). The initial study by Derecki et al. transplanted wild-type (WT) bone marrow (BM) into an irradiated mouse model of RTT, *Mecp2* null mouse (*Mecp2^-/y^(Mecp2^tm1.1Jae/y^)*)prior to phenotypic symptom onset (\~4 weeks of age) ([@bib19]). When WT BM-derived microglia-like cells engrafted the CNS, many RTT-like phenotypes were arrested and lifespan was significantly increased. While data suggested that phagocytic activity of microglia may be disrupted in *Mecp2 *null mice, it remained unclear precisely how microglia were contributing to the disorder. In a follow-up study, these data were replicated using a more specific, tamoxifen-inducible Cre driver on a *Mecp2* null background (*Cx3cr1^Cr^*^eER^*; Mecp2^lox--stop/y^*) ([@bib15]). In addition, RNAseq analysis revealed abnormalities in glucocorticoid signaling, hypoxia responses, and inflammatory responses in peripheral macrophages and resident brain microglia isolated from *Mecp2 *null mice. While these data support a role for myeloid-derived MeCP2 in RTT phenotypes and pathology, another recent study demonstrated little to no effect of re-introducing MeCP2 into myeloid cells by BM chimerism in three different RTT mouse models (*Mecp2^tm1.1Jae/y^, Mecp2^LucHyg/y^* and *Mecp2^R168X/y^ *mice), or by genetic expression of MeCP2 in hematopoietic cells (including microglia) in a MeCP2 null background (*Vav1-Cre; Mecp2^LSL/Y^*) ([@bib67]). Thus, it remains unclear if and how microglia, specifically, contribute to pathogenesis.

Recent work in the healthy, developing CNS has demonstrated a surprising new role for microglia in synaptic circuit remodeling and maturation ([@bib59]; [@bib66]; [@bib65]; [@bib55]). Among the functions at developing synapses, we recently showed in the retinogeniculate system that microglia contribute to the process of removing excess synapses by phagocytosing less active or 'weaker' presynaptic inputs ([@bib58]). Importantly, disrupting microglial phagocytic activity resulted in sustained increases in synapse density and connectivity into adulthood. In the current study, we hypothesized that microglia-mediated synaptic remodeling were abnormal in mouse models of neurodevelopmental disorders associated with aberrant brain wiring and chose RTT to test this hypothesis. In many different RTT mouse models, synaptic circuit dysfunction can be detected often prior to presentation of significant phenotypic abnormalities ([@bib71]; [@bib4]; [@bib16]; [@bib17]; [@bib51]; [@bib68]; [@bib52]; [@bib50]; [@bib49]). This includes work in the retinogeniculate system where decreases in single fiber synaptic strength are detected at early stages of disease followed by changes in structural circuits at late phenotypic stages ([@bib52]). In addition, studies assessing synapse density in postmortem human and mouse brain tissue have identified abnormalities, including reductions in synapse number ([@bib51]; [@bib12]; [@bib21]; [@bib36]; [@bib63]; [@bib69]; [@bib11]).

Here, using the retinogeniculate system, we examined the interactions between microglia and synapses before, during, and after the onset of phenotypic regression in the *MeCP2 *null mouse (*Mecp2^tm1.1Bird/y^*) ([@bib28]). Furthermore, we use Cre-lox technology to specifically ablate or express *Mecp2 in* microglia and determine whether these cells play a causative role in the structural and functional synaptic abnormalities. Our data demonstrate that microglia play a role in pathogenesis of synapses by excessively engulfing presynaptic inputs at end stages of disease in the visual system; however, this effect is largely secondary and independent of microglia-specific loss of Mecp2 expression.

Results {#s2}
=======

Microglia engulf presynaptic inputs during a newly identified wave of synaptic refinement in the healthy, late-juvenile retinogeniculate system {#s2-1}
-----------------------------------------------------------------------------------------------------------------------------------------------

The retinogeniculate system, a classic model for studying multiple waves of developmental synapse refinement, is comprised of retinal ganglion cells (RGCs) residing in the retina that project to relay neurons in the lateral geniculate nucleus (LGN) of the thalamus ([@bib25]; [@bib31]; [@bib34]). We previously established that microglia contribute to early phase synapse refinement by engulfing, thereby eliminating, presynaptic inputs at P5 ([@bib58]). Synaptic engulfment was subsequently downregulated during later waves of refinement (P9-P30) ([@bib25]; [@bib31]; [@bib33]; [@bib64]). It was unknown whether microglia regulate presynaptic input density after P30. Given that Mecp2 null mice begin to phenotypically regress ≥P30 and continue regression until premature death \~P60 ([@bib9]; [@bib26]; [@bib45]; [@bib28]), we first needed to establish a baseline engulfment in \>P30 WT mice.

Recently, a new late wave of refinement was identified between P30 and P60 in which RGC arbors decrease in size and presynaptic boutons decrease in number ([@bib32]). We hypothesized that microglia were contributing to this late phase refinement by transiently engulfing synapses between P30 and P60. We first confirmed a reduction in retinogeniculate synapses in the late, juvenile brain of WT mice by immunolabeling P30-P60 LGN with antibodies against the RGC-specific presynaptic protein vesicular glutamate transporter 2 (VGlut2), and the postsynaptic protein Homer1 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). There was a significant reduction in the density of RGC-specific synapses (VGlut2/Homer1-positive) and a reduction in VGlut2-positive terminal size between P30 and P60 ([Figure 1---figure supplement 1A--F](#fig1s1){ref-type="fig"}). This was in contrast to VGlut1-positive corticocortical synapses, which remain unchanged ([Figure 1---figure supplement 1G--I](#fig1s1){ref-type="fig"}). To determine whether microglia contribute to late phase synaptic remodeling in the late, juvenile brain and establish a baseline to assess whether these interactions are disrupted in phenotypic *Mecp2* null mice, we next used our established assay to monitor microglia-synapse interactions in the retinogeniculate system ([@bib58], [@bib57]). One day prior to analysis, RGC inputs were labeled by injection of anterograde dye into both eyes, cholera toxin conjugated to Alexa dye 594 or 647 (CTB-594 or CTB-647), which is resistant to lysosomal degradation. Microglia were labeled by either genetic expression of EGFP (*Cx3CR1^EGFP/+ ^*mice) or by immunohistochemistry using an antibody specific to the microglia-marker, Iba-1. Lysosomes that are specific to and within microglia were labeled with an antibody against CD68. Similar to previously published work ([@bib58]), microglia preferentially engulfed RGC inputs within the LGN at P5 ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) compared to older ages. However, our new data revealed a second wave of engulfment that occurred in the juvenile brain specifically at P40, which is downregulated by P50 ([Figure 1A--B](#fig1){ref-type="fig"}) and accompanied by a transient increase in lysosomal content within microglia ([Figure 1C](#fig1){ref-type="fig"}). Together with recent work demonstrating decreases in RGC arbor size and bouton numbers between P30 and P60 ([@bib32]), our work suggests that microglia contribute to this fine-scale refinement by engulfing RGC presynaptic inputs at P40.10.7554/eLife.15224.003Figure 1.Microglia transiently engulf retinogeniculate presynaptic inputs in the juvenile P40 brain consistent with late stage synapse refinement.(**A**) Representative surface rendered microglia (green) and engulfed retinogeniculate inputs (red) from P30, P40, and P60 LGN. See also [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}. Grid line increments = 5 µm. (**B**) Quantification of engulfment reveals a transient and significant increase in engulfment of RGC inputs within microglia at P40, an age consistent with late-stage synaptic refinement ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). (**C**) Accompanying increased engulfment, microglia also upregulate engulfment capacity at P40 as measured by lysosomal content within each microglia (CD68 immunoreactivity per cell). \*p\<0.05, \*\*p\<0.01 by one-way ANOVA, Dunnett's post hoc test (all ages are compared to P60). All error bars represent SEM; N = 4--6 mice per age of mixed sex (equal ratios of males and females were used across ages).**DOI:** [http://dx.doi.org/10.7554/eLife.15224.003](10.7554/eLife.15224.003)10.7554/eLife.15224.004Figure 1---figure supplement 1.Refinement of structural synapses in the late juvenile retinogeniculate system.(**A--B**) Immunohistochemistry in P30 (**A**) and P60 (**B**) dLGN for vesicular glutamate transporter 2 (VG2) to label RGC-specific presynaptic terminals (ii, green in iv) and Homer1 to label postsynaptic densities (iii, red in iv). DAPI was used to label nuclei (i). Scale bar = 20 µm. (**C--F**) Quantification reveals a developmental decrease between P30 and P60 in structural VG2+ terminal size (**C**), VG2+ terminal density (**D**), and VG2+ synapse density (co-localized VG2 and Homer1) (**F**). (**G--I**) Quantification of immunohistochemistry for vesicular glutamate transporter 1 (VG1) to label corticothalamic-specific presynaptic terminals reveals no significant difference in VG1+ terminals (**G--H**) or VG1-containing synapses (**I**, colocalized VG1 and Homer1) in P30 vs P60 dLGN. \*p\<0.05 by Student's t-test. All error bars represent SEM; N = 3--4 per age.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.004](10.7554/eLife.15224.004)10.7554/eLife.15224.005Figure 1---figure supplement 2.Presynaptic input engulfment in early and late phases of synaptic refinement in the developing retinogeniculate system.Engulfment of retinogeniculate presynaptic inputs is significantly increased in P5 and P40 LGN compared to P50. \*p\<0.05, \*\*\*p\<0.001 by one-way ANOVA, Dunnett's post hoc test (all ages are compared to P60). All error bars represent SEM; N = 4--6 mice per age.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.005](10.7554/eLife.15224.005)

Microglia engulf excessive presynaptic inputs in late phenotypic *Mecp2 *null mice {#s2-2}
----------------------------------------------------------------------------------

Phenotypic regression is evident in *Mecp2* null mice by P40. Furthermore, these abnormalities occur after the onset of electrophysiological weakening of single fiber synaptic responses in the P20-P30 *Mecp2* null retinogeniculate system ([@bib52]). We hypothesized that microglia-mediated engulfment of retinogeniculate inputs in P40, juvenile mice was enhanced in *Mecp2* null mice with weakened synapses.

Similar to experiments described to assess engulfment in the juvenile WT brain, RGC presynaptic inputs from both eyes were labeled with CTB-594 or CTB-647 and microglia were labeled by either genetic expression of EGFP (Cx3CR1 ^EGFP/+^; *Mecp2^-/y^*or Cx3CR1^EGFP/+^; *Mecp2^+/y^*) or immunolabeling with anti-Iba-1. In addition, to measure lysosomal content, microglia were labeled with anti-CD68. Using these methods, we detected no significant difference in microglia-mediated engulfment of retinogeniculate presynaptic inputs in P5-P50 WT or *Mecp2* null mice compared to WT littermate controls ([Figure 2C](#fig2){ref-type="fig"}). However, in late phenotypic P56-P60 ([\>]{.ul}P56) *Mecp2 *null mice, we found significant increases in engulfed inputs and lysosomal content within microglia processes and soma compared to WT littermates ([Figure 2A--D](#fig2){ref-type="fig"}). Consistent with engulfment being specific to synaptic compartments, we observed no significant RGC death in the retina or LGN ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) and we observed no changes in engulfment of other neuronal compartments including NeuN-positive somas or MAP2-positive dendrites ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). In addition and in contrast to previously published reports ([@bib15]; [@bib37]), we observed no significant changes in morphology (as measured by volume of the cell) or density of microglia, indexes of the gross, overall reactive state of these cells ([Figure 2E--F](#fig2){ref-type="fig"}). However, our analyses were restricted to microglia within the LGN, a region that was not analyzed previously ([@bib15]; [@bib37]). These data demonstrate that, while microglia-mediated waves of synaptic engulfment are normal in the P5 and P40 *Mecp2 *null brain, engulfment is excessive in ≥P56 mice---an age corresponding to late stages of phenotypic regression ([@bib28]). Furthermore, this timing occurs after significant weakening of single fiber strength at *Mecp2 *null retinogeniculate synapses ([@bib52]). These data suggest that microglia do not actively induce circuit defects in *Mecp2* null mice but rather facilitate late stage circuit defects by removing previously weakened structural synapses.10.7554/eLife.15224.006Figure 2.Microglia excessively engulf retinogeniculate presynaptic inputs in late phenotypic *Mecp2* null mice.(**A--B**) Representative surface rendered microglia (green) and engulfed RGC inputs (red) demonstrates enhanced engulfment of presynaptic inputs in ≥P56 (P56-P60) *Mecp2* null dLGN (**B**) as compared to WT littermate controls (**A**). Grid line increments = 5 µm. (**C**) Quantification of engulfment across development reveals excessive engulfment of presynaptic inputs within ≥P56 *Mecp2* null dLGN as compared to WT littermate controls in the absence of significant RGC cell death ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) or engulfment of other non-synaptic neuronal debris ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). \*p\<0.05 by multiple unpaired Student's t-tests; N = 4--6 mice per age and genotype; all data are normalized to WT controls at each age. (**D**) Quantification of lysosomal content (CD68 immunoreactivity) within microglia in ≥P56 LGN reveals a significant increase in phagocytic capacity in *Mecp2* null mice as compared to WT littermate controls. \*\*p\<0.01 by unpaired Student's t-tests; N = 3 mice per genotype; data are normalized to WT control. (**E--F**) There is no significant difference in numbers or volume of microglia within the ≥P56 LGN by unpaired Student's t-test; N = 3--5 mice per genotype; data are normalized to WT control. All error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.006](10.7554/eLife.15224.006)10.7554/eLife.15224.007Figure 2---figure supplement 1.There is no significant cell death in the retinas of *Mecp2* null mice.(**A--B**) Quantification of total DAPI (**A**) and NeuN (**B**) cells in the retinal ganglion cell layer of the retina from ≥P56 *Mecp2* WT (grey bars) and null (red bars) mice reveals no significant changes in cell numbers. All error bars represent SEM; N = 3 mice per genotype. (**C**) Immunohistochemistry in the Mecp2 WT (top) or null (bottom) retina for TUJ1 (red) to label the retinal ganglion cell layer or cleaved caspase (green) to label dead/dying cells. Cleaved caspase channel is visualized separately in far right panels for both genotypes. Cell death was never observed in either genotype. Data are representative of 3 mice per genotype. Scale bar = 100 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.007](10.7554/eLife.15224.007)10.7554/eLife.15224.008Figure 2---figure supplement 2.Engulfment is specific to presynaptic inputs.(**A**) A representative maximum intensity projection of a microglia (EGFP, green) and neurons labeled with anti-NeuN (blue), and anti-MAP2 (red) in the ≥P56 (P56-P60) *Mecp2* null LGN. Scale bar = 5 µm. (**C**) Surface rendering of the same microglia (**A**) and engulfed MAP2 and NeuN-positive debris (arrows). Grid line increments = 5 µm. (**C--D**) Quantification of engulfed MAP2 (**C**) or NeuN (**D**) immunoreactive neuronal debris reveals no significant difference between Mecp2 WT (grey bars) and null animals (red bars). Error bars represent SEM; N = 3 mice per genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.008](10.7554/eLife.15224.008)

Retinogeniculate presynaptic terminals and synapses are reduced in late phenotypic *Mecp2 *null mice {#s2-3}
----------------------------------------------------------------------------------------------------

We next assessed whether increased engulfment in P56-P60 (≥P56) *Mecp2 *null mice corresponded to loss of structural retinogeniculate synapses. We first immunolabeled retinogeniculate presynaptic terminals in P40 and P56-P60 (≥P56) *Mecp2 *null and WT littermate brains with an antibody directed against VGlut2. While there was no change in the density of VGlut2 immunoreactivity in P40 *Mecp2 *null mice compared to WT littermate controls, there was a significant decrease at ≥P56, a time point corresponding to late-stage phenotypic regression in *Mecp2 *null mice ([Figure 3A--D](#fig3){ref-type="fig"}). To determine whether this reduction in VGlut2 was consistent with a loss of synapses, we further assessed P56-P60 (≥P56) *Mecp2 *null mice for changes in retinogeniculate synapse density defined as co-localized presynaptic VGlut2 and postsynaptic Homer1 immunoreactivity. Consistent with the reduction in VGlut2 and excessive synaptic engulfment, there was a significant decrease in retinogeniculate synapses in P56-P60 (≥P56) *Mecp2 *null mice as compared to WT littermate controls ([Figure 3](#fig3){ref-type="fig"}) and this synapse loss was due to loss of VGlut2-positive terminals ([Figure 3C](#fig3){ref-type="fig"}) versus a decrease in the postsynaptic protein Homer1 ([Figure 3H](#fig3){ref-type="fig"}) or RGC cell death ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Retinogeniculate synapses represent \<10% of total synapses within the LGN ([@bib6]). To assess the other more abundant excitatory synapses, we immunolabeled corticogeniculate synapses with an antibody against VGlut1 within the LGN and observed no significant difference in the density of these synapses or presynaptic terminals. ([Figure 3---figure supplement 1A--E](#fig3s1){ref-type="fig"}). In addition, we assessed VGlut2 and VGlut1-positive synapse density in a neighboring thalamic nuclei (medial geniculate nucleus, MGN; [Figure 3---figure supplement 1F--G](#fig3s1){ref-type="fig"}) and observed no significant loss of these structural synapses. These results demonstrate a specific loss of retinogeniculate presynaptic terminals in late phenotypic ≥P56 *Mecp2 *null mice concomitant with increased microglia-mediated engulfment of presynaptic inputs.10.7554/eLife.15224.009Figure 3.Retinogeniculate presynaptic terminals and synapses are reduced in late phenotypic ≥P56 *Mecp2* null mice.(**A**) Immunohistochemistry for VGlut2 to label retinogeniculate presynaptic terminals, in the dLGN of P40 (**A**) and ≥P56 (**B**, P56-P60) *Mecp2* wild-type (WT; left column) and null (right column) littermates. Images are single planes of a confocal z-stack. Scale bar = 20 µm. (**C--D**) Quantification of RGC presynaptic terminal (VGlut2+ puncta) immunohistochemistry reveals a significant decrease in RGC-specific terminal density (**C**) and size (**D**) in ≥P56 *Mecp2* null mice (red bars) as compared to WT littermate controls (grey bars). No significant difference was observed at P40. All data are normalized to WT control for each age. \*\*p\<0.01 unpaired Student's t-test at each age; N = 3--4 mice per age and genotype; (**E--F**) Immunohistochemistry for VGlut2 (green) and the postsynaptic marker Homer1 (in the dLGN of ≥P56 *Mecp2* WT (**E**) and null (**F**) littermates. Images are single planes from confocal z-stacks. The VGlut2 and Homer1 channels are separated in panels ii--iii. Panels Eiv and Fiv are colocalized VGlut2 and Homer1 puncta. Scale bar = 10 µm. (**G--H**) Quantification reveals a a significant decrease in RGC-specific synapses (colocalized VGlut2 and Homer) within the LGN of [\>]{.ul}P56 *Mecp2* null mice (red bars) as compared to WT littermate controls (grey bars) (**G**) and no significant change in the density of the postsynaptic protein Homer1 (**H**). No significant difference in density was observed in corticogeniculate-specific, VGlut1-positive synapses within the LGN or VGlut2 or VGlut1-containing synapses within a neighboring thalamice nuceli ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). \*p\<0.05 by Student's paired t-test.; N = 5 mice per genotype; all data are normalized to WT control. All error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.009](10.7554/eLife.15224.009)10.7554/eLife.15224.010Figure 3---figure supplement 1.Presynaptic terminal and synapse loss are specific to retinogeniculate synapses.(**A--B**) Immunohistochemistry for the corticogeniculate presynaptic terminal marker VGlut1 (green) and the postsynaptic marker Homer in the dLGN of ≥P56 *Mecp2* WT (**A**) and null (**B**) littermates. Images are single planes from confocal z-stacks. The VGlut1 and Homer channels are separated in panels ii-iii. Colocalized VGlut1 and Homer puncta are visualized in panels Aiv and Biv. Scale bar = 10 µm. (**C**--**E**) Quantification reveals no significant difference in the density of VGlut1-positive terminals (**C**), Homer-positive postsynaptic densities (**D**), or colocalized VGlut1/Homer puncta (**E**) in the LGN of ≥P56 *Mecp2* null mice (red bars) as compared to WT littermate controls (grey bars). (**F--G**) Quantification of density of VGlut2 (**F**) and VGlut1 (**G**) presynaptic terminals in the medial geniculate nucleus (MGN) of ≥P56 *Mecp2* WT (grey bars) and null (red bars) mice reveals no significant changes in terminal density in this neighboring thalamic nuclei. All error bars represent SEM; N = 4--5 mice per genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.010](10.7554/eLife.15224.010)

Microglia-specific loss of *Mecp2* expression is insufficient to induce excessive engulfment, synapse loss, or phenotypic regression {#s2-4}
------------------------------------------------------------------------------------------------------------------------------------

To address how loss of *Mecp2* expression specifically affects microglia function, we crossed *Mecp2^fl/y^ *mice with *Cx3cr1^CreER^* mice to conditionally ablate *Mecp2* in microglia following tamoxifen injection ([@bib15]; [@bib24]; [@bib70]). To achieve microglia-specific *Mecp2* ablation, tamoxifen was injected at P21-P25 and mice were assessed \~2.5 months later (P110-P120; [Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Consistent with microglia performing a secondary role, we found no significant increase in retinogeniculate synapse engulfment or RGC presynaptic terminal (VGlut2-positive) loss when *Mecp2* was ablated specifically in microglia *(Cx3cr1^CeER/+^;Mecp2^fl/y^ *Tam, blue hashed bars) as compared to all control groups ([Figure 4B--C](#fig4){ref-type="fig"}).10.7554/eLife.15224.011Figure 4.Excessive engulfment, synapse loss, and phenotypic regression are not induced following microglia-specific loss of *Mecp2* expression.(**A**) Paradigm for inducing recombination in which mice receive 2 tamoxifen or vehicle (oil) injections 48 hr apart between P21 and P25 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Behavior and postmortem analyses are subsequently performed in P110-P120 mice. (**B--C**) Quantification of engulfment (**B**) and VGlut2 terminal density (**C**) in the LGN of oil (solid bars) or tamoxifen (Tam, hashed bars)-treated mice expressing *Cx3cr1^CreER/+^;Mecp2^fl/y^ *(blue bars) *or Cx3cr1^CreER/+^;Mecp2^+/y^*(grey bars) reveals no significant effect when *Mecp2* expression is specifically ablated in microglia (*Cx3cr1^CreER/+^;Mecp2^fl/y^ *Tam, blue hashed bars) compared to all control groups. N = 4--6 mice per genotype (**D--G**). Quantification of neurological scores, weight loss, latency to fall from a rotarod, and behavioral visual acuity (optometry) in oil (solid bars) or tamoxifen (Tam, hashed bars)-treated mice expressing *Cx3cr1^CreER/+^;Mecp2^fl/y^ or Cx3cr1^CreER/+^;Mecp2^+/y^. *There is no significant difference between mice with Mecp2-deficient microglia (*Cx3cr1^CreER/+^;Mecp2^fl/y^ *Tam, blue hashed bars) versus the same genotype treated with oil (*Cx3cr1^CreER/+^;Mecp2^fl/y^ *Oil blue solid bars) in any assays. However, there is a small but significant deficit in neurological score (**D**) and visual acuity (**G**) when comparing mice with Mecp2-deficient microglia (*Cx3cr1^CreER/+^;Mecp2^fl/y^ *Tam, blue hashed bars) to WT controls (*Cx3cr1^CreER/+^;Mecp2^+/y^*, grey bars), an effect likely due to the hypomorphic *Mecp2^fl/y^ *allele. \*p\<0.05, \*\*p\<0.01 by one-way ANOVA, Tukey's post hoc test; N = 7--13 mice per genotype. All error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.011](10.7554/eLife.15224.011)10.7554/eLife.15224.012Figure 4---figure supplement 1.Validation of Cre-mediated recombination and Mecp2 deletion in microglia.(**A--E**) *Cx3CR1^CreER^* mice were crossed with Ai9 (RCL-tdT) mice which harbor a targeted mutation of the *Gt(ROSA)26Sor* locus with a *loxP*-flanked STOP cassette that prevents transcription tdTomato. Mice were administered tamoxifen at P21-P25 and assessed for recombination [\>]{.ul}P80. (**A--B**) Images demonstrating colocalization between Iba-1 positive microglia (green) and tdTomato-positive cells (red) in the LGN and cortex. Scale bar = 100 µm. (**C--D**) Magnified regions from **A** and **B**. Scale bar = 100 µm. (**E**) Quantification of images reveals that nearly 100% of Iba-1 positive microglia were positive for tdTomato (green bar) and nearly 100% of td Tomato-positive cells were positive for Iba-1 (red bar). Error bars represent SEM; N = 3 mice. (**F**) PCR for the intact (*\~*500) and the excised *mecp2fl allele (\~400 bp)* on genomic DNA of microglia isolated from whole brains of *Cx3cr1^CreER/+^:Mecp2^fl/y^ *mice, treated or non-treated tamoxifen (TAM) in vivo. (**G**) Flow cytometric analysis of microglia isolated from whole brains of TAM-treated *Cx3cr1^CreER/+;^ Mecp2^+/y^*and *Cx3cr1^CreER^;Mecp2^fl/y^ *mice reveals loss of Mecp2 protein in *Cx3cr1^CreER^:Mecp2^fl/y^ *mice (red line). (**H**) Immunohistochemistry in the LGN for Mecp2 (C-terminal antibody was a generous gift from Dr. M. Greenberg) following antigen retrieval and amplification using HRP-conjugated secondary antibodies reveals Mecp2 protein (red) within the nucleus (DAPI, blue) of Iba-1-positive microglia in WT (top row) animals (yellow arrow) and loss of Mecp2 specifically in microglia (red arrow) following recombination in *Cx3cr1^CreER^;Mecp2^fl/y^* mice (P110-P120; bottom row). Merged and individual channels are shown as well as magnified region of Mecp2 channel (far right panels). Scale bar =10 µm. It should be noted that several other Mecp2 antibodies and staining conditions were attempted, but only this antibody and condition enabled us to detect Mecp2 protein even in WT microglia. (**I**) Quantification of Mecp2 expression in microglia reveals a significant loss of Mecp2 protein following recombination in *Cx3cr1^CreER^;Mecp2^fl/y^* mice. \*\*\*\*p\<0.0001 by Student's t-test. Error bars represent SEM; N = 3 mice per genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.012](10.7554/eLife.15224.012)

We also assessed other general phenotypic abnormalities known to be significantly affected in *Mecp2* null animals including overall neurological score, weight loss, rotarod performance and the optomotor task, an assessment of behavioral visual acuity previously shown to be significantly decreased in *Mecp2* null mice ([Figure 4D--G](#fig4){ref-type="fig"}) ([@bib20]). We observed no significant defects in weight loss or rotarod performance in mice that lacked *Mecp2* specifically in microglia *(Cx3cr1^CeER/+^;Mecp2^fl/y^ *Tam, blue hashed bars), as compared to all controls ([Figure 4E--F](#fig4){ref-type="fig"}). Neurological score and optomotor task performance ([Figure 4D,G](#fig4){ref-type="fig"}) were also not significantly different between mice that lacked Mecp2 in microglia *(Cx3cr1^CreER/+^;Mecp2^fl/y^ *Tam, blue hashed bars) and the same genotype treated with oil *(Cx3cr1^CreER/+^;Mecp2^fl/y^ *Oil, blue solid bars). However there was a small but significant effect when compared to WT controls (*Cx3cr1^CreER/+^;Mecp2^+/y^*, gray bars), an effect which may be confounded by the hypomorphic *Mecp2^fl/y^ *allele (see Discussion) ([@bib56]; [@bib39]). Together, these data demonstrate that loss of Mecp2 in microglia is largely insufficient to induce excessive engulfment, synapse loss or phenotypic abnormalities.

Microglia-specific *Mecp2* expression is largely insufficient to attenuate abnormalities in microglia, synapses, or phenotypes in *Mecp2* null mice {#s2-5}
---------------------------------------------------------------------------------------------------------------------------------------------------

In addition to assessing mice that specifically lack *Mecp2* expression in microglia, we did the converse experiment using a similar tamoxifen injection paradigm to express *Mecp2* specifically in microglia in an otherwise *Mecp2* null background *(Cx3cr1^CreER/+^;Mecp2^LSL/y^)* ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Similar mice have been assessed by other groups and have generated differing results\--one group demonstrated significant attenuation of phenotypes, while another group observed no effect ([@bib19]; [@bib15]; [@bib67]). We sought to assess microglia dysfunction, synapse loss, and general phenotypes in *Cx3cr1^CreER/+^;Mecp2^LSL/y^* and clarify these disparate results.10.7554/eLife.15224.013Figure 5.*Mecp2* expression in microglia is largely insufficient to attenuate excessive engulfment, synapse loss, or phenotypic regression in *Mecp2* null mice.(**A**) Paradigm for inducing recombination in which mice receive 2 tamoxifen or oil injections 48 hr apart between P21 and P25. Behavior and postmortem analyses are subsequently performed in P78-P90 mice ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). (**B--C**) Quantification of engulfment (**B**) and VGlut2 terminal density (**C**) in the LGN of oil (solid bars) or tamoxifen (hashed bars)-treated mice expressing *Cx3cr1^CreER/+^;Mecp2^LSL/y^ *(red bars) or *Cx3cr1^CreER/+^;Mecp2^+/^*^y^ (grey bars). (**B**) There was a significant decrease in VGlut2 terminal density in mice null for *Mecp2* in all cells (red solid bars) and this effect was attenuated when *Mecp2* was expressed in microglia (red hashed bars), an effect which may have resulted from tamoxifen treatment which induces a trend towards increased VGlut2 density in WT mice (grey hashed bars). \*p\<0.05, \*\*p\<0.01 by one-way ANOVA, Tukey's post hoc test; N = 4--6 mice per genotype. (**C**) In addition, there is a significant increase in engulfment in mice null for *Mecp2* in all cells (red solid bars) compared to WT, oil-treated littermates (grey solid bars) and this effect was not significantly attenuated when *Mecp2* was expressed in microglia (red hashed bars). However, expression of Mecp2 in microglia is no longer significant from controls, which suggests a modest effect. \*p\<0.05 by one-way ANOVA, Dunnett's post hoc test (all genotypes compared to *Cx3cr1^CreER/+^;Mecp2^+/y^* Oil, grey bars; data are not significant by Tukey's post hoc test); N = 3--5 mice per genotype. All error bars represent SEM. (**D--G**) Expression of *Mecp2* in a null background (red hashed bars) has no significant effect on attenuation of deficits in neurological score (**D**) weight loss (**E**) latency to fall from a rotarod (**F**) or visual acuity (**G**) compared to mice null for *Mecp2* in all cells (red bars). However, rotarod performance in *Cx3cr1^CreER/+^;Mecp2^LSL/y^* Tam mice (red hashed bar) was no longer significant from controls (grey hashed and solid bars), which suggests a modest effect. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 by one-way ANOVA, Tukey's post hoc test; N = 6--11 mice per genotype. All error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.013](10.7554/eLife.15224.013)10.7554/eLife.15224.014Figure 5---figure supplement 1.Validation of loss or gain of Mecp2 protein in dLGN microglia following Cre-mediated recombination.(**A**) Immunohistochemistry in the LGN for Mecp2 (C-terminal antibody was a generous gift from Dr. M. Greenberg) following antigen retrieval and amplification using HRP-conjugated secondary antibodies reveals Mecp2 protein (red) within the nucleus (DAPI, blue) of Iba-1-positive microglia in WT (top row) and Cx3CR1^CreER/+^;Mecp2^LSL/y^ (bottom row) animals treated with tamoxifen (yellow arrows) and loss of Mecp2 in all cells including microglia (red arrow) in *Cx3cr1^CreER^;Mecp2^fl/y^* mice treated with oil (middle row). Merged and individual channels are shown as well as magnified region of Mecp2 channel (far right panels). Scale bar = 10 µm. (**B**) Quantification of Mecp2 expression in microglia reveals a significant loss of Mecp2 protein in *Cx3cr1^CreER^;Mecp2^LSL/y^* mice treated with oil compared to Cx3CR1^CreER/+^;Mecp2^+/y^ or Cx3CR1^CreER/+^;Mecp2^LSL/y^ treated with tamoxifen. \*\*\*\*p\<0.0001, \*\*\*p\<0.001 by one-way ANOVA. Error bars represent SEM; N = 3 mice per genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.014](10.7554/eLife.15224.014)

We first assessed whether microglia-specific *Mecp2* expression was sufficient to attenuate excess engulfment and synapse loss in *Mecp2* null mice. Similar to ≥P56 *Mecp2* null mice, there was a significant increase in engulfment and decrease in RGC presynaptic terminal density in late phenotypic P78-P90 *Mecp2^LSL/y^ *treated with oil *(Cx3cr1^CreER/+^;Mecp2^LSL/y^* Oil, red solid bars) as compared to *Mecp2^+/y^* controls (grey bars, [Figure 5B--C](#fig5){ref-type="fig"}). When *Mecp2 was expressed* in microglia in a null background (*Cx3cr1^CreER/+^;Mecp2^LSL/y^* Tam, red hashed bars), the excessive engulfment was not attenuated compared to the same genotype treated with oil (*Cx3cr1^CreER/+^;Mecp2^LSL/y^* Oil, red solid bars). However, engulfment was no longer significantly different from *Mecp2^+/y^* controls (grey solid and hashed bars), which suggests a modest effect. In contrast, there was a significant enhancement in RGC terminal density in *Cx3cr1^CreER/+^;Mecp2^LSL/y^* treated with tamoxifen (red hashed bars) compared to null animals (red solid bars; [Figure 5C](#fig5){ref-type="fig"}). Tamoxifen administration alone (*Cx3cr1^CreER/+^;Mecp^+^*^/*y*^ Tam, grey hashed bars) however, had a trend towards increased VGlut2 density in WT mice ([Figure 5C](#fig5){ref-type="fig"}), which suggests this effect may result from tamoxifen treatment.

We next assessed general phenotypes and behavioral visual acuity in *Cx3cr1^CreER/+^;Mecp2^LSL/y^*mice. We did not observe a significant improvement in neurological score, weight loss, or visual acuity and only a small improvement in rotarod performance when *Mecp2* was specifically expressed in microglia ([Figure 5D--G](#fig5){ref-type="fig"}, *Cx3cr1^CreER/+^;Mecp2^LSL/y^*Tam, red hashed bars). Together with data from *Cx3cr1^CreER/+^;Mecp2^fl/y^*mice, excessive engulfment, synapse loss, and phenotypic abnormalities are largely independent of microglia-specific loss or gain of *Mecp2* expression. Our data are most consistent with recent reports that microglia-specific Mecp2 expression is insufficient to attenuate phenotypes in *Mecp2* null mice ([@bib67]).

Discussion {#s3}
==========

Our results demonstrate that microglia-mediated engulfment of presynaptic inputs is a plastic event that can be transiently upregulated during multiple waves of synaptic remodeling in the healthy, developing brain. Furthermore, engulfment of presynaptic inputs is upregulated and excessive in late phenotypic *Mecp2* null mice, concomitant with loss of structural synapses. Cre-lox experiments demonstrate that microglia-specific loss of *Mecp2* expression does not induce excessive engulfment or synapse loss and, similarly, gain of microglia-specific *Mecp2* expression in a null background also has little effect on attenuation of these parameters. Furthermore, deficits in general phenotypic abnormalities and behavioral visual acuity are also largely independent of microglia-specific loss or gain of *Mecp2* expression. Along with mice that express *Mecp2* specifically in microglia on a null background, these data offer significant insight into the contribution of these cells to disease progression. Taken together, our data suggest a model where loss of *Mecp2* expression in microglia has minimal effect on neural circuit integrity and function. Instead, microglia largely respond secondarily and engulf synapses in response to circuits weakened and rendered vulnerable by loss of *Mecp2* in other resident CNS cell types such as neurons and astrocytes.

Microglia-mediated presynaptic engulfment in the healthy, juvenile brain {#s3-1}
------------------------------------------------------------------------

In the process of establishing a baseline of engulfment in the WT juvenile brain, we identified a new window of microglia-mediated presynaptic engulfment at P40 ([Figure 2](#fig2){ref-type="fig"}). This age corresponds to a newly identified window of late-stage, fine-scale structural synapse elimination in the retinogeniculate system ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib32]). One open question is what molecular mechanism underlies this late-stage engulfment and, if disrupted, are there sustained deficits in circuit structure and function.

In early postnatal development (first postnatal week), we previously identified that microglia engulf presynaptic inputs, in part, through complement-dependent phagocytosis ([@bib58]). Mice deficient in the microglial phagocytic receptor, complement receptor 3 (CR3), or complement components C3 and C1q had sustained deficits in engulfment and synaptic remodeling in the retinogeniculate system ([@bib58]; [@bib5]; [@bib62]). Furthermore, this process was dependent upon neural activity whereby microglia preferentially engulfed less active or 'weaker' presynaptic inputs. It is unknown whether this late phase presynaptic input engulfment is dependent upon complement or activity. Given that CR3 and C3 (the ligand for CR3) decrease over development and C3, in particular, is very low/undetectable in the juvenile brain ([@bib58]; [@bib62]; [@bib61]), it is likely that another mechanism underlies microglia-synapse interactions in juvenile animals. It is also clear that this late-stage presynaptic input engulfment is independent of *Mecp2*, as engulfment at P40 is indistinguishable from WT littermates ([Figure 3C](#fig3){ref-type="fig"}). Future work to assess other molecular pathways underlying microglia-synapse interactions in the juvenile brain will be important going forward.

Microglia excessively engulf presynaptic inputs in the *Mecp2* null brain {#s3-2}
-------------------------------------------------------------------------

While in vitro work has suggested that loss of Mecp2 in microglia can affect glutamate-mediated neurotoxicity and synapses ([@bib37]; [@bib47]), it was unknown whether microglia affect synapses in Mecp2 null mice in vivo. Furthermore, while deficits in glutamatergic, glucocorticoid, hypoxia, and immune-related pathways have recently been reported in *Mecp2 *null microglia ([@bib15]; [@bib19]; [@bib37]; [@bib47]), it has remained unclear precisely how microglia were contributing to disease on a mechanistic level in vivo. Our data offer significant insight into these unanswered questions. We demonstrate that microglia excessively engulf presynaptic inputs in the *Mecp2* null LGN concomitant with loss of structural retinogeniculate-specific synapses in the same region. These data are in contrast to previously published work that has suggested microglial phagocytic activity is decreased compared to WT mice ([@bib19]). However, this discrepancy can be explained by differences in experimental design used to measure phagocytic activity. Assays used to measure phagocytosis in previous work were in vitro in response to the addition of UV-irradiated neural precursor cells ([@bib19]), a context that is very different from assessing engulfment of presynaptic inputs in the retinogeniculate system in vivo. In the same study, annexin V was administered in vivo to block phagocytic activity in *Mecp2* null mice with WT BM-derived cells (*Mecp2^LSL/y^/Lysm^Cre^*), which resulted in failure of *WT* BM-derived cells to attenuate phenotypes in *Mecp2^LSL/y^ *mice. However, it is unclear where and how annexin V is acting given that phagocytosis was not directly assayed in vivo and the *Lysm^Cre^* induces expression in many myeloid-derived cell types besides microglia. Indeed, this same group published findings that loss of *Mecp2* primarily affects peripheral myeloid-derived cell numbers and gene expression early in disease and only later affects microglia ([@bib15]). Going forward, it will be important to understand the contribution of these peripheral cell types to disease phenotypes.

To address whether microglia were primary or secondary to synapse loss, we used Cre-lox technology to specifically express or ablate *Mecp2* in microglia. In doing so, we demonstrate that synapse loss and excessive engulfment in *Mecp2* null mice are largely independent of microglial-specific loss of *Mecp2* expression. This is inconsistent with data in which re-expression of *Mecp2*in myeloid-derived cells (including microglia) attenuates several behavioral phenotypes and cell loss in *Mecp2* null mice ([@bib19]; [@bib15]). However, our data are consistent with data from this same group suggesting that microglia in *Mecp2* null mice are abnormal only in late phenotypic mice, suggesting a secondary effect ([@bib15]). Furthermore, our data are consistent with the newest report from a different group that re-expression of *Mecp2 *in myeloid cells (including microglia) does not attenuate phenotypes in *Mecp2* null or mutant mice ([@bib67]).

While our data suggest that microglia are largely secondary responders to synapses rendered vulnerable by loss of Mecp2 in other CNS cell types, the significance of excessive synaptic engulfment to disease progression is still unknown. The molecular mechanism driving secondary engulfment of synapses in *Mecp2* null mice and whether modulating this excessive engulfment results in attenuation of synapse loss are also unknown. Complement-dependent phagocytic signaling is one mechanism by which microglia have been shown to engulf synapses in the healthy brain, a pathway which is also dysregulated in disease ([@bib58]; [@bib60]; [@bib13]; [@bib30]; [@bib43]). In addition, there are a number of other inflammatory genes that have been identified as dysregulated in *Mecp2 *null microglia and may contribute to increased phagocytic activity ([@bib15]). Finally, we demonstrate that microglia are largely secondary responders in two mouse models of RTT (*Mecp2* null and *Mecp2^LSL/y^*). It is still possible that microglia may be primary initiators of synaptic defects in other RTT models (*Mecp2^-/+^, Mecp2* duplication, *Mecp2^R270X^~ ~*etc.), a mechanism recently reported in mouse models of frontotemporal dementia and Alzheimer\'s disease ([@bib9]; [@bib13]; [@bib2]; [@bib8]; [@bib30]; [@bib43]). Assessing microglia function at synapses in these other disease-relevant models will be important future directions going forward.

Minimal role for microglia in mediating phenotypic regression in *Mecp2* null mice {#s3-3}
----------------------------------------------------------------------------------

Ablating *Mecp2* expression specifically in microglia had little effect on phenotypic regression ([Figure 4](#fig4){ref-type="fig"}). The minimal effect observed when comparing *Cx3cr1^CeER/+^;Mecp2^fl/y^ *tamoxifen-treated mice to WT controls (*Cx3cr1^CreER/+^;Mecp2^+/y^*) is likely due to the *Mecp2^fl/y^ *hypomorphic allele. The *Mecp2^fl/y^* mice have reduced *Mecp2* expression and develop RTT phenotypes in the absence of Cre-mediated recombination ([@bib56]; [@bib39]), effects which may become apparent if the trajectory of phenotypes were assessed after P120. Similarly, expression of *Mecp2* specifically in microglia in an otherwise null animal ([Figure 5](#fig5){ref-type="fig"}) had little to no effect on attenuation of any phenotype assessed. Together, our data are most consistent with the recent report that WT microglia/myeloid cells have no effect on phenotypes in *Mecp2 *null or mutant mice but rather phenotypes are more likely due to loss of *Mecp2* expression in other CNS cell types such as neurons or astrocytes ([@bib67]; [@bib41]; [@bib23]; [@bib44]; [@bib10]; [@bib35]). Our data are in contrast to two other reports from another group that demonstrate introducing *Mecp2* in microglia and other myeloid cells on a *Mecp2 null* background results in significant attenuation of phenotypes ([@bib19]; [@bib15]). The discrepancy may result from difference in paradigms used to express *Mecp2*. For example, in our study, we induced recombination with tamoxifen in *Cx3cr1^CreER/+^;Mecp2^LSL/y^ *mice at P21-P25 and assessed phenotypes at ≥P78. This paradigm results in purely microglia-specific expression of *Mecp2* due to ongoing hematopoiesis that replaces peripheral *Mecp2*-null cells with WT cells ([@bib24]; [@bib70]). In contrast, Cronk, Derecki et al. induced recombination in these same mice at 9 weeks (\~P63) [@bib15]. This late tamoxifen administration may be necessary to observe significant effects on phenotypes and may result from expression of *Mecp2* in peripheral myeloid cells. Furthermore, previous work by this same group demonstrated a significant attenuation of phenotypic regression in *Mecp2 null* mice after BM transplantation at P28 and engraftment with WT myeloid cells by \~P84 or with Cre mediated recombination (*Lysm^Cre^*) in myeloid cells from birth [@bib19]. These paradigms also affect *Mecp2* expression in peripheral immune cells. Thus, we speculate that these divergent results may be due to differences in peripheral myeloid-derived cell-specific *Mecp2* expression, which is intriguing and worthy of future investigation. It should also be noted that we did not measure the entire panel of phenotypic abnormalities (breathing, open field, etc.) or survival so it is unknown if our results differ in these contexts. Finally, it is unclear how recently published data using a similar BM chimerism strategy but a different Cre mouse (Vav1-Cre) resulted in contradictory results and is also worthy of follow-up investigation ([@bib67]).

Summary {#s3-4}
-------

There have been conflicting reports regarding if and how microglia contribute to phenotypes in mouse models of RTT ([@bib19]; [@bib15]; [@bib67]). Our data offer significant insight into how microglia contribute to disease in *Mecp2* null mice. While microglia-specific loss of *Mecp2* is largely insufficient to induce synapse loss and phenotypic regression and gain of Mecp2 in expression in *Mecp2* null mice is insufficient to attenuate these parameters, microglia contribute secondarily by dismantling synaptic circuits in complete *Mecp2* null mice. Taken together with previously published data that single fiber strength decreases during early stages of phenotypic regression in the *Mecp2* null retinogeniculate system ([@bib52]), we propose that microglia dismantle neural circuits in the late phenotypic *Mecp2* null brain by engulfing synapses previously rendered vulnerable and weakened by loss of *Mecp2* expression in, most likely, neurons. Given that recent studies demonstrate the reversibility of circuit defects and phenotypes in RTT mouse models ([@bib19]; [@bib42]; [@bib41]; [@bib23]; [@bib44]; [@bib15]; [@bib27]; [@bib38]; [@bib7]; [@bib22]; [@bib53]; [@bib18]; [@bib46]), identifying a molecular mechanism by which microglia dismantle circuits during late phenotypic stages and determining whether this is critical to end-stages of disease will be an important future directions with therapeutic potential.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

*Cx3cr1^EGFP/+^*, Ai9 (RCL-tdT), *MeCP2^-/y^* (*Mecp2^tm1.1Bird/y^), Mecp2^LSL/y^ (Mecp2^tm2Bird/y^),* and *Mecp2^fl/y^ (Mecp^tm1Bird/y^)* mice were obtained from Jackson Labs (Bar Harbor, MA) and *Cx3cr1^CreER/+^* mice were obtained from Jonathan Kipnis, University of Virginia. All mice were maintained by breeding to C57BL/6J. For some engulfment experiments, *MeCP2^-/+^* female mice were crossed with male *Cx3cr1^EGFP/EGFP^*mice. For Cre-lox experiments, *Mecp2^LSL/+^*or *Mecp2^fl/+^* female mice were crossed with male *Cx3cr1^CreER/CreER^* mice. All experiments using *Cx3cr1^EGFP/+^*or *Cx3cr1^CreER/+^* mice were performed with heterozygotes. Unless otherwise noted in figure legend, experiments were performed in male mice. For Cre-lox experiments, P21-P25 *Cx3cr1^CreER/+^*-expressing mice were injected with tamoxifen (20 mg/kg; Sigma Aldrich, Natick,MA) or vehicle (corn oil; Sigma Aldrich, Natick,MA) subcutaneously two times, 48 hr apart, a protocol previously demonstrated to induce efficient recombination ([@bib24]; [@bib70]). All experiments were approved by institutional animal use and care committees and performed in accordance with all NIH guidelines for the humane treatment of animals.

Engulfment analysis {#s4-2}
-------------------

Analysis of engulfment was performed using previously published procedures ([@bib58], [@bib57]). Briefly, both eyes were injected with the same fluorophore-conjugated tracer (either cholera toxin β subunit conjugated to Alexa dye 594 (CTB-594) or 647 (CTB-647) (Life Technologies, Carlsbad, CA). Mice were then sacrificed 24 hr later. Brains were fixed in 4% paraformaldehyde (PFA; EMS, Hatfield, PA) for 3--4 hrs and 40 µm thick sections were prepared. Sections were further immonstained with antibodies against Iba-1 (Wako Chemicals, Richmond, VA) and/or CD68 (AbD Serotec, Raleigh, NC) to measure lysosomal content as previously described ([@bib58]). For analysis of non-synaptic material, adjacent brain sections were immunolabeled with antibodies against Iba-1 (Wako Chemicals, Richmond, VA), NeuN (EMD Millipore, Darmstadt, Germany), and MAP2 (EMD Millipore, Darmstadt, Germany). Sections were then imaged on a UltraView Vox spinning disk confocal microscope equipped with diode lasers (405 nm, 445 nm, 488 nm, 514 nm, 561 nm, and 640 nm) and Volocity image acquisition software (Perkin Elmer, Waltham, MA). Two LGN sections were imaged per animal and 4-63x fields of view were collected from the dorsal and ventral regions of each dLGN (8 fields of view total per animal). Images were subsequently processed in Image J (NIH) and analyzed using Imaris software (Bitplane, Zurich, Switzerland) as previously described ([@bib58], [@bib57]).

Synapse density quantification {#s4-3}
------------------------------

Synapses were quantified similar to previously published work with modifications ([@bib58]). Briefly, mice were either perfused with 4% PFA followed by a 2 hr drop fix in 4% PFA or fixed identical to those methods described for engulfment analysis (see above). Tissue sections 15 or 40 µm) were subsequently prepared and immunostained for synaptic proteins. Antibodies included anti-Homer1 (Synaptic Systems GmbH, Goettingen, Germany), anti-Vesicular Glutamate Transporter 2 (VGlut2; EMD Millipore, Darmstadt, Germany), and anti-VGlut1 (EMD Millipore, Darmstadt, Germany) followed by appropriate, species-specific secondary antibodies conjugated to Alexa dyes (Life Technologies, Carlsbad, CA). Immunostained sections were imaged with a 63x Zeiss pan-Apochromat oil, 1.4 NA objective on a Zeiss LSM 700 Laser Scanning Confocal equipped with diode lasers (405, 488, 555 and 633 nm) and Zen image acquisition software (Carl Zeiss, Oberkochen, Germany). Alternatively, sections were imaged with a Leica SP8 X confocal (Wetzlar, Germany) equipped with multiple laser lines (405, 458, 488, 496, 514, and 470--670 nm white light) using a HC PL APO 63x/1.40 oil CS2 or a HC PL APO 40x/1.10 W motCORR (only 40 µm-thick sections) objective and LasX software. To maintain consistency across animals, the most medial dLGN sections were chosen for imaging. A total of 3 confocal z-stacks (1 µm spacing) were then collected from dorsal, medial, and ventral regions of the dLGN section. For each z-stack, (2 confocal planes with the most robust DAPI staining were subsequently chosen and analyzed for blind analysis using Image J software (NIH, Bethesda, MD). As a result, a total of 6 single confocal planes were analyzed for each animal. Fluorescent images of pre and/or postsynaptic markers were separated and thresholded blind. Density of thresholded pre and/or postsynaptic markers were calculated using the measure particles function where a puncta size was defined and maintained for all analyses across animals for each marker (VGlut2 = 0.2-infinity; Homer1 = 0.1-infinity; VGlut1 = 0.1-infinity). The colocalization of puncta was quantified subsequently using the Image Calculator function applied to thresholded pre and postsynaptic images. The size and area of each puncta were recorded and then the total puncta area and average puncta size were calculated for each animal. The synapse or terminal densities were calculated by taking the total puncta area and dividing it by the total area of the field of view. The puncta density and puncta size were averaged across fields for each animal.

Quantification of cell number and cell death {#s4-4}
--------------------------------------------

Samples were prepared and imaged similar to methods described for engulfment and synapse density quantification (see above). For microglia numbers, 10 x fields of vew were collected and cells were counted blind using the point tool in Image J. For cell death analysis, retinas were immunolabeled with antibodies against cleaved caspase 3 (Cell Signaling Technology, Danvers, MA), TUJ1 (BioLegend (formerly Covance) San Diego, CA) or NeuN (EMD Millipore, Darmstadt, Germany), mounted with media containing DAPI (Vectashield; Vector Labs, Burlingame, CA), and 4 fields of view (20X) were collected. Cells were counted blind for each field of view using the point tool in Image J.

Validation of loss or gain of Mecp2 protein by immunohistochemistry {#s4-5}
-------------------------------------------------------------------

For validation of loss or gain of Mecp2 protein in microglia, a subset of tissue sections collected for engulfment or synapses analysis were selected and subjected to antigen retrieval using Retrievagen A (BD Biosciences, San Jose, CA). Briefly, sections were microwaved (power = 2) for 5 min in Retrievagen A solution. This was repeated once and then sections were washed 3 times with 0.1 M phosphate buffer. Sections were then immunostained with a rabbit antibody directed against the C-terminus of Mecp2 (a generous gift from M. Greenberg Harvard Medical School) ([@bib3]) and a chicken antibody against Iba-1 (Abcam, Cambridge, MA), overnight at room temperature. Sections were then washed and HRP-conjugated rabbit and Alexa fluor-conjugated rat antibodies were added to the sections for 1--2 hr at room temperature. Sections were subsequently washed and an Alexa-fluor conjugated anti-HRP antibody was added overnight at 4 degrees. After the overnight incubation, sections were mounted and imaged. It should be noted that several other Mecp2 antibodies and staining conditions were attempted, but only this antibody and condition enabled us to detect Mecp2 protein even in WT microglia. Two 63x fields of view were collected in the lateral, medial, and ventral portions of the LGN per animal (3 animals per condition) and images were assessed for Mecp2-positive microglia.

Genomic DNA extraction for validating loss or gain of Mecp2 expression {#s4-6}
----------------------------------------------------------------------

Sorted cells were lysed and digested in TES buffer (10 mM Tris buffer, pH = 8, 5 mM EDTA, 0.1 M NaCL, 0.5% SDS and 100 ug PK) overnight in 56°C. DNA was precipitated in 70% ethanol for 30 mins at room temperature, centrifuged twice at top speed and the tubes were left to dry. Pellets were reconstituted with TE buffer for subsequent PCR. Genomic PCR for *Mecp2* gene was performed using the following primers: 5\'-TGGTAAAGA CCCATGTGACCCAAG-3\', 5\'-GGCTTGCCACATGACAAGAC-3\', 5\'-TCCACCTAG CCTGCCTGTACTTTG-3\'.

Tissue extraction and flow cytometry {#s4-7}
------------------------------------

Brain samples were harvested from individual mice and tissues were homogenized and incubated with a HBSS solution containing 2% BSA (Sigma-Aldrich), 1 mg/ml collagenase D (Roche), and 0.15 mg/ml DNase1, filtered through a 70 µm mesh. Homogenized sections were filtered through 80 μM wire mesh and resuspended in 40% Percoll, prior to density centrifugation (1000 x *g*. 15 min at 20°C with low acceleration and no brake). Cells were acquired on LSRFortessa systems (BD) and analyzed with FlowJo software (Tree Star). For cell sorting, the FacsAria (BD) was used. Antibodies used include: CD11b (clone M1/70; AbD Serotec, Raleigh, NC), CD45 (clone 30F11; AbD Serotec, Raleigh, NC), and MeCP2 (EMD Millipore, Darmstadt, Germany).

Behavioral visual acuity (optomotor task) {#s4-8}
-----------------------------------------

Acuity was measured blind using methods identical to those previously described ([@bib20]; [@bib54]).

Rotarod {#s4-9}
-------

Rotarod performance was measured blind using methods similar to those previously described ([@bib19]; [@bib14]). One day prior to training, mice were acclimated to a non-accelerating rotarod 5 RPM for 5--10 min. The following day, the animals were tested for performance (latency to fall) on an accelerating rotarod over 5 trials, which were subsequently averaged to plot an average latency to fall for each animal.

Neurological scoring {#s4-10}
--------------------

Neurological scores were recorded blind using methods similar to those previously described ([@bib19]; [@bib14]). Mice were scored on a scale from 0 to 2, with '0' being no phenotype, and '2' being severe phenotype. For gait, mice were assessed for wide-spread hind limbs and waddling while locomoting. Hind limb clasping was assessed by suspending mice by the tail and assessing clenching of hind limbs across the ventral aspect of the body. Tremor was characterized as a visible involuntary shaking and was scored based on the severity. Appearance was scored based on the presence or lack of grooming and/or hunched posture. The scores were subsequently summed to give a neurological score.

Statistical analyses {#s4-11}
--------------------

For all statistical analyses, GraphPad Prism 5 software (La Jolla, CA) was used. Analyses used include unpaired Student's t-test, one-way ANOVA, or two-way ANOVA with 95% confidence and appropriate post hoc analyses (indicated in figure legends). All p and N values are indicated in figure legends. All N's represent biological replicates (number of mice used for the study). Sample size was chosen based on our previous work analyzing engulfment and synapse density and work by other groups assessing phenotypic changes in *Mecp2* mutant mice ([@bib19]; [@bib15]; [@bib58]; [@bib28]; [@bib57]; [@bib20]; [@bib41]; [@bib10]; [@bib27]; [@bib53]).
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Decision letter

Barres

Ben

Reviewing editor

Stanford School of Medicine

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Microglia contribute to circuit defects in *Mecp2* null mice independent of microglia-specific loss of *Mecp2* expression\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

There are two major weaknesses regarding proof of *Mecp2* manipulation and the validity of using homer in the synapse analyses. These should be addressed with new experiments and analyses. Considering how controversial this field is, it is important that the authors demonstrate *Mecp2* knockout in microglia. Once those issues are cleared though, this paper would make a valuable contribution to the field.

Reviewer \#1:

MECP2 mutations in humans cause majority of the Rett Syndrome cases, an X-linked neurodevelopmental disorder with severe intellectual and motor phenotypes. Previous studies suggested that the function of this gene in microglia is critically impaired in the disease. Moreover, rescue of some of the disease phenotypes in Rett model mice was observed, following bone marrow transplantation after irradiation. However, other studies did not replicate these findings, making it unclear whether microglial *Mecp2* function is involved in Rett syndrome pathogenesis.

This manuscript by Dr. Schafer and colleagues investigate the function of *Mecp2* gene specifically in microglial synaptic pruning using the mouse retinogeniculate system.

The manuscript starts with the demonstration of a previously uncharacterized early adult pruning event that occurs around P40 in the wildtype mouse geniculate. They find that synaptic pruning, measured as the engulfment of labeled RGC terminals, is unaffected in P5-P50 *Mecp2* KO mice compared to WT. But in *Mecp2*-KO mice (that are older than 56 days) there is enhanced axonal terminal engulfment and lysosomal content in microglia. They then use global null and conditional loss- or gain-of-function alleles of *Mecp2* in combination with CX3CR1-CreER to specifically silence or rescue the expression of *Mecp2* in microglia. They find that manipulations of *Mecp2* expression in microglial have little effect on excessive engulfment, structural and functional visual circuit defects, or other general phenotypes associated with *Mecp2*-function. Based on these results the authors conclude that microglial contribution to Rett syndrome is likely to be secondary after the loss of *Mecp2* function in other CNS cell types.

The article is well-written, and the reported experimental data provide compelling evidence in support of the authors\' conclusions. Use of multiple genetic approaches in combination with rigorous analysis of microglial phenotypes is impressive. However, the manuscript currently does not present any evidence for effective *Mecp2* gene manipulation using CX3CR1-CreER. Without such evidence we cannot exclude the possibility that the observed minimal phenotypes are due to ineffective manipulation of *Mecp2* expression in microglia by CX3CR1-CreER. Moreover, there are several other concerns with regards to how the synapses were quantified, which are detailed below. The authors should provide new data and analyses to address these concerns.

1\) Lack of evidence showing effective modification of *Mecp2* gene in microglia by CX3CR1-CreER. CX3CR1-CreER transgenic mouse line was thoroughly characterized and confirmed as a good tool to silence gene expression in microglia. However, (as with any Cre line used in a conditional gene manipulation paradigm) the authors should demonstrate that using their tamoxifen injection paradigm, in their brain region of interest, the microglial expression of *Mecp2* is altered. Without such assurance it is hard to exclude that ineffective *Mecp2* manipulation in microglia in general or the geniculate microglia in particular leads to the observed weak phenotypes. Considering how controversial this particular field is, the authors should provide this crucial control so their results are fully supported. Effectiveness of this manipulation in multiple animals should be demonstrated to be able to exclude the possibility of variability between individual mice.

2\) Quantification of synapse number in the geniculate. The authors use an imaging-based technique to estimate geniculate synapses. This technique, the quantification of co-localized pre and postsynaptic protein signals, is appropriate; however, the provided images show that homer staining is very dense and potentially mostly not synaptic. At the resolution and magnification of the provided images it is hard to conclude whether VGlut2 and homer are truly co-localizing or is it just pure chance. Also the materials and method section describing how this quantification was done is not detailed. Where in geniculate did the pictures originate? It is important that the images were acquired from the same area in different animals so they could be comparable. How were the images acquired? Was the analysis performed on single optical sections or maximum projections? Also VGlut1 synapses were quantified as well, but no representative images are provided, so it is hard to evaluate the quality of staining on which that analysis was based.

Reviewer \#2:

In this paper Schafer and colleagues investigate the role of microglia in the Rett syndrome (*Mecp2* null mouse). They first focus on the pruning role of microglia and find that this is normal at the onset of the disease but it increases at later stages. They also demonstrate that gain and -most importantly- loss of the *Mecp2* gene in microglia has little effect on engulfment and on characteristic Rett phenotypes. Thus, the main conclusion here is that microglia cannot be considered major contributors in Rett pathology.

This is clearly a \"non-discovery\" but it is an important one because it resolves conflicting reports on this matter. The controversy is exemplified but the clashing titles of the two major publications on this topic: \"Wild-type microglia arrest pathology in a mouse model of Rett syndrome\" (Derecki et al. Nature 2015) and \"Wild-type microglia do not reverse pathology in mouse models of Rett syndrome\" (Wang et al. Nature 2015). Thus, I believe the work of Schafer and colleagues to be of value and to deserve publication in a rigorous and respected journal.

There are few points, however, that need to be clarified and better demonstrated.

1\) The authors show that at later stages *Mecp2* microglia have more phagosomes containing pre-synaptic inputs. This increase can be explained by active synaptic remodeling but also by engulfment of neurons within the *Mecp2* brain. They exclude the latter by comparing the number of neurons and nuclei in wildtype and *Mecp2* null. Considering the large number of cells in the brain this cannot be considered a sensitive method and needs to be backed up by a direct visualization and quantification of neuronal (non-synaptic) material in microglia. If microglia are involved in active synaptic remodeling they should not show increased -generic- neuronal markers in their phagosomes. This point is critical also considering that in *Mecp2* null microglia there 3 times more lysosomes ([Figure 2D](#fig2){ref-type="fig"}). Considering that only a smaller fraction contains synaptic material (compare graph in [Figure 2C](#fig2){ref-type="fig"} with [Figure 2D](#fig2){ref-type="fig"}) the authors should exclude that these vesicles contain non-synaptic material resulting from the engulfment of entire neurons.

2\) Throughout this paper the authors write that microglia at later stages in the *Mecp2* null mouse remove weaken synapses. That microglia can remove weaken synapses was shown by Schafer and colleagues in their 2012 Neuron paper. Here, however, they give no evidence that in *Mecp2* microglia remove weaker synapses. They should remove these statements or provide evidence for this.

3).Please, note that in. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} the postsynaptic protein Homer1 is visible at P30 (iii) but not at P60 (iii) nevertheless the staining is quantified in E.

4\) In [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} it is written that engulfment of presynaptic inputs is significantly increased over old ages. Judging from the graph the opposite is true.

Reviewer \#2 (Additional data files and statistical comments):

The authors have stained *Mecp2* and wild-type with an anti-activated-Caspase 3 antibody. Please, include these data.

10.7554/eLife.15224.019

Author response

There are two major weaknesses regarding proof of Mecp2 manipulation and the validity of using homer in the synapse analyses. These should be addressed with new experiments and analyses. Considering how controversial this field is, it is important that the authors demonstrate Mecp2 knockout in microglia. Once those issues are cleared though, this paper would make a valuable contribution to the field.

We have added new data to existing figures, added an additional 3 supplemental figures ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), and made substantial revisions to the text to address all reviewer concerns. Please see detailed responses to each concern.

Reviewer \#1:

*1) Lack of evidence showing effective modification of Mecp2 gene in microglia by CX3CR1-CreER. CX3CR1-CreER transgenic mouse line was thoroughly characterized and confirmed as a good tool to silence gene expression in microglia. However, (as with any Cre line used in a conditional gene manipulation paradigm) the authors should demonstrate that using their tamoxifen injection paradigm, in their brain region of interest, the microglial expression of Mecp2 is altered. Without such assurance it is hard to exclude that ineffective Mecp2 manipulation in microglia in general or the geniculate microglia in particular leads to the observed weak phenotypes. Considering how controversial this particular field is, the authors should provide this crucial control so their results are fully supported. Effectiveness of this manipulation in multiple animals should be demonstrated to be able to exclude the possibility of variability between individual mice.*

We have spent significant time and resources addressing this particular concern. One major issue was that attaining enough RNA or protein from microglia isolated from the LGN for qPCR or western blot was not technically feasible and/or required a large amount of animals from lines of mice that do not reproduce well. As a result, we attempted immunohistochemistry on our existing tissue (from engulfment and synapse analysis experiments) to detect *Mecp2* protein in LGN microglia. For several weeks we tried many different antibodies and staining conditions and were never able to detect *Mecp2* protein even in wild-type microglia (see [Author response image 1](#fig6){ref-type="fig"} for a subset of attempts). This is likely due to very low expression of *Mecp2* in microglia (Zhang et al. J. Neurosci 2014). However, we finally achieved success using a non-commercially available rabbit *Mecp2* antibody developed by and obtained from Dr. Michael Greenberg. Using this antibody directed against the C-terminus of *Mecp2* combined with antigen retrieval and HRP amplification (Ballas et al. Nat Neurosci2009), we were able to detect low levels of *Mecp2* protein in 40-50% of wild-type LGN microglia and *Mecp2* expression was either lost with recombination in *Cx3CR1~CreER/WT~;Mecp2~fl/y~*+TAM or *Cx3CR1~CreER/WT~;Mecp2~LSL/y~*+Oil mice or gained in *Cx3CR1~CreER/WT~;Mecp2~LSL/y~*+TAM mice (see new Figures: [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In addition, we performed other experiments to show sufficient recombination including analysis of efficiency and specificity of tdTomato expression following tamoxifen injection in *Cx3CR1~CreER/WT~*;Rosa26-tdTomato mice (see new [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We also performed PCR on genomic DNA and FACs analysis to assess protein expression in microglia isolated from the whole brain of *Cx3CR1~CreER/WT~;Mecp2~fl/y~*+TAM mice (see new [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).10.7554/eLife.15224.015Author response image 1.Attempts to immunostain for *Mecp2* protein in WT LGN microglia.To validate loss or gain of *Mecp2* expression, we first required an antibody to recognize *Mecp2* protein in WT microglia. We made numerous attempts before we were able to detect adequate levels for analysis (see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Failed attempts are in LGN microglia are shown. Merge channels are on top row and the *Mecp2* channel is in the bottom row. Arrows denote microglia nuclei and lack of *Mecp2* immunostaining in bottom panel. (**A**) Immunostaining with a Millipore chicken anti- *Mecp2* antibody with antigen retrieval (red in Ai, Aii) and anti-Iba-1 to label microglia. (B-C) Immunostaining with a C-terminal anti-*Mecp2* antibody (gift from M. Greenberg from Harvard Medical School; red in Bi and Ci, Bii and Cii) and anti-Cd11b to label microglia without (**B**) and with (**C**) amplification using HRP. We were successful detecting *Mecp2* in microglia with this antibody following antigen retrieval and HRP amplification (see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). (**D**) Immunostaining with a Millipore rabbit anti-Mecp2 antibody with HRP amplification (red in Di, Dii) and anti-Cd11b to label microglia. All Scale bars =10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.015](10.7554/eLife.15224.015)

2\) Quantification of synapse number in the geniculate. The authors use an imaging-based technique to estimate geniculate synapses. This technique, the quantification of co-localized pre and postsynaptic protein signals, is appropriate; however, the provided images show that homer staining is very dense and potentially mostly not synaptic. At the resolution and magnification of the provided images it is hard to conclude whether VGlut2 and homer are truly co-localizing or is it just pure chance. Also the materials and method section describing how this quantification was done is not detailed. Where in geniculate did the pictures originate? It is important that the images were acquired from the same area in different animals so they could be comparable. How were the images acquired? Was the analysis performed on single optical sections or maximum projections? Also VGlut1 synapses were quantified as well, but no representative images are provided, so it is hard to evaluate the quality of staining on which that analysis was based.

The main conclusion of this part of the paper is that we see changes in presynaptic inputs and thus a decrease in structural synapses (juxtaposed pre and postsynaptic elements). There is no significant change in the postsynaptic (or even extrasynaptic) Homer immunoreactivity. We have updated the manuscript to better clarify this point and included quantification of Homer immunoreactivity (see updated [Figure 3](#fig3){ref-type="fig"}). In addition, the representative images in the original manuscript ([Figure 3](#fig3){ref-type="fig"}) were maximum intensity projections as we felt this most fully demonstrated the loss of presynaptic inputs (the main conclusion). However, this was at the expense of postsynaptic staining appearing relatively non-specific and dense. Given that the analysis was actually performed on single confocal planes, we modified this figure to include single planes which better show co- localization (see updated [Figure 3](#fig3){ref-type="fig"}).

The reviewer also raises questions regarding the synaptic localization of Homer. We originally chose Homer given that, out of all postsynaptic markers, it gave us the most consistent and strong signal to noise. Interestingly, retinogeniculate synapses represent \<10% of presynaptic inputs in the LGN (Bickford et al. J Comp Neurol2009). We have noted this in the revised manuscript. Thus, while it is appreciated that some Homer immunoreactivity could be extrasynaptic, our data are consistent with a large proportion of Homer immunoreactivity as postsynaptic and colocalized with other non- RGC (non-VGlut2 positive) terminals. This is demonstrated by increased co-localization of Homer/VGlut1 versus Homer/ VGlut2 (see updated [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Author response image 2](#fig7){ref-type="fig"}). We have also included [Author response image 3](#fig8){ref-type="fig"} demonstrating that VGlut2 terminals also co- localize with another postsynaptic marker, anti-PSD-95, to a similar degree as Homer. Furthermore, to address whether colocalization occurs purely by chance, we rotated the VGlut2 channel 90 degrees and performed co-localization analysis. This analysis demonstrates that there is higher cumulative probability of colocalization in correctly oriented VGlut2/Homer or VGlut2/PSD-95 images as compared to those in which the VGlut2 channel was rotated (see [Author response image 3](#fig8){ref-type="fig"}).10.7554/eLife.15224.016Author response image 2.VGlut1-containing synapses are more abundant than VGlut2- containing synapses within the dLGN.Quantification of the density of VGlut1 or VGlut2 immunoreactive puncta colocalized with Homer. Data were collected from 4-5 P60 wild-type mice. Error bars represent ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.016](10.7554/eLife.15224.016)10.7554/eLife.15224.017Author response image 3.Postsynaptic proteins colocalize with VGlut2 more frequently over chance.(**A**) Single plane of a confocal z-stack in the adult wild-type dLGN immunostained with anti-VGlut2 (white), anti-Homer (green, Aii), and anti-PSD-95 (red, Aiii). Scale bar=10 µm. (**B--C**) Cumulative probability of co-localized Homer (**B**) or PSD- 95 (**C**) with VGlut2 before (solid line) or after 90 degree rotation (dashed line) of the VGlut2 channel. Colocalization of both postsynaptic proteins is more probable over chance (90 degree rotation). Data were collected and averaged across 3 adult wild- type animals (2 single plane images from the same region were collected and analyzed for each animal). D.Result of colocalization analysis between VGlut2 and Homer (Di) and VGlut2 and PSD-95 (Dii). Result of colocalization upon 90 degree rotation of the VGlut2 channel.**DOI:** [http://dx.doi.org/10.7554/eLife.15224.017](10.7554/eLife.15224.017)

As requested by the reviewer, we have also included representative images of VGlut1/Homer staining (see updated [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) and we updated the Materials and methods section to more extensively describe the data collection. Briefly, for each animal, 3 confocal z stacks were taken in the same regions of the dLGN. Then, 2 planes out of each z-stack were chosen blindly based on the most abundant DAPI staining for analysis. As a result, a total of 6 images were analyzed in nearly identical locations were analyzed across animals.

*Reviewer \#2:*

*There are few points, however, that need to be clarified and better demonstrated.*

1\) The authors show that at later stages Mecp2 microglia have more phagosomes containing pre-synaptic inputs. This increase can be explained by active synaptic remodeling but also by engulfment of neurons within the Mecp2 brain. They exclude the latter by comparing the number of neurons and nuclei in wildtype and Mecp2 null. Considering the large number of cells in the brain this cannot be considered a sensitive method and needs to be backed up by a direct visualization and quantification of neuronal (non-synaptic) material in microglia. If microglia are involved in active synaptic remodeling they should not show increased -generic- neuronal markers in their phagosomes. This point is critical also considering that in Mecp2 null microglia there 3 times more lysosomes ([Figure 2D](#fig2){ref-type="fig"}). Considering that only a smaller fraction contains synaptic material (compare graph in [Figure 2C](#fig2){ref-type="fig"} with [Figure 2D](#fig2){ref-type="fig"}) the authors should exclude that these vesicles contain non-synaptic material resulting from the engulfment of entire neurons.

We appreciate the reviewers comment and have done more analysis of engulfment of non- synaptic material including NeuN immunoreactive neuron cell somas and Map2-immunoreactive somato-dendritic domains within the LGN (see updated [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We do not observe an increase in engulfment of these neuronal compartments as compared to presynaptic input engulfment. This is consistent with our data and previously published work demonstrating no neuronal cell death in the mouse models of Rett Syndrome or in human patients (reviewed in Chahrour and Zoghbi Neuron 2007; Banerjee et al. Front Psychiatry 2012). This reviewer does raise an interesting point as to what exactly, if anything, occupies these remaining lysosomes. While outside the scope of the current manuscript, this would be an interesting future direction.

2\) Throughout this paper the authors write that microglia at later stages in the Mecp2 null mouse remove weaken synapses. That microglia can remove weaken synapses was shown by Schafer and colleagues in their 2012 Neuron paper. Here, however, they give no evidence that in Mecp2 microglia remove weaker synapses. They should remove these statements or provide evidence for this.

We suggest that microglia engulf weakened synapses. This is based on previous electrophysiology demonstrating an overall weakening of retinogeniculate synapses by P30 (Noutel et al. Neuron 2011), a timepoint preceding any significant signs of engulfment. While we still suggest this as a possibility in the manuscript, we have toned down the language and removed this from the overall conclusions.

3\) Please, note that in. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} the postsynaptic protein Homer1 is visible at P30 (iii) but not at P60 (iii) nevertheless the staining is quantified in E.

These data do appear in our pdf version of the manuscript, which was downloaded for review at *eLife*. It should be noted that the Homer staining pattern does differ across ages (soma and small puncta staining at P30 versus only puncta staining at P60). This point was raised by Reviewer 1 and it may have some biological significance and differences in extrasynaptic (somatic) versus synaptic (small puncta) homer localization.

4\) In [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} it is written that engulfment of presynaptic inputs is significantly increased over old ages. Judging from the graph the opposite is true.

We apologize. This was poorly written. We modified the figure legend to better reflect that, as the reviewer correctly points out, engulfment is higher at P5 and P40 versus P60.

*Reviewer \#2 (Additional data files and statistical comments):*

*The authors have stained Mecp2 and wild-type with an anti-activated-Caspase 3 antibody. Please, include these data.*

We have included these data in the revised manuscript (see updated [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).
